The findings indicate that an antisense oligodeoxynucleotide specifically aimed at TGFB2 notably enhanced overall survival in younger patients with pancreatic ductal adenocarcinoma when compared to older patients. The gene discussed is TGFB2; the disease is pancreatic ductal adenocarcinoma.